

Appendix 2 (as supplied by the authors): Summary of risk-of-bias assessment of included studies using Cochrane's risk-of-bias tool* [1]

Study	Sequence Generation	Allocation Concealment	Blinding of Participants/ Personnel	Blinding of Outcome Assessors			Incomplete Reporting			Selective Reporting	Other Bias
				OBJ	SUB	S-R	OBJ	SUB	S-R		
Anderssen 1995 [2]	U	L	H	L	U		L	L		L	L
Andrews 2011 [3]	L	L	H	L	H		L	L		L	U
Appel 2011 [4]	L	U	H	L	L	H	L	L	L	L	L
Balducci 2010 [5]	U	U	U	L	U		L	L		L	H
Bakris 1992 [6]	U	U	U	L	U	U	H	H	H	L	U
Bennett 2012 [7]	L	U	H	L	U	H	L	L	L	L	L
Berne 2004 [8]	L	U	U	L	U	U	L	L	L	L	H
Broom 2002a [9]	L	U	U	L	U	U	H	H	H	L	H
Broom 2002b [10]	U	U	U			U			H	L	H
Burke 2005 [11]	L	U	H		U			H		L	L
Burtscher 2012 [12]	U	U	H	L	U		L	L		L	H
Christian 2008 [13]	L	L	H	L	U		L	L		L	L
Cohen 1991 [14]	U	U	H		U			L		L	H
Davidson 1999 [15]	U	U	U	L	U	U	H	H	H	L	H
Dekkers 2011 [16]	L	L	H	L	U		H	H		L	L
de Mello 2012 [17]	U	U	H	L	L		L	L		L	L
Derosa 2003 [18]	L	L	L	L	L	L	L	L	L	L	H
Derosa 2012 [19]	L	L	L	L	L	L	L	L	L	L	L
DPP 1999 [20]	L	U	H	L	U	H	U	U	U	L	H
Finer 2000 [21]	L	L	U	L	L	L	H	H	H	L	H
Fontbonne 1996 [22]	U	U	U	L	U	U	L	L	L	L	H
Foster-Schubert 2012 [23]	L	U	H	L	L		L	L		L	L
Haapala 2009 [24]	U	U	U		U			H		L	H
Hanefeld 2002 [25]	U	U	U			U			H	L	H
Hauptman 2000 [26]	U	U	U	L	U	U	H	H	H	H	U
He 2012 [27]	L	L	L			L			L	L	L
Hollander 1998 [28]	U	U	U	L	U	L	L	L	L	L	H
Janney 2010 [29]	U	U	H		U	U		H	H	L	L
Janus 2012 [30]	L	L	H	L	U		L	L		L	L
Kelley 2002 [31]	U	U	U	L	U	U	H	H	H	U	H
Krempf 2003 [32]	U	U	U	L	U	U	H	H	H	L	H
Kirby 2011 [33]	U	U	H	L	U		H	H		L	L

Kopelman 2010 [34]	U	U	U	L	U	L	L	L	L	L	L	H
Kulzer 2009 [35]	U	U	H	L	L		L	L		L	L	H
Langford 1985 [36]	U	U	H		U			U		L	L	H
Lim 2010 [37]	U	U	U	L	U		H	H		L	L	H
Lim 2011 [38]	L	L	U			L			H	U	L	L
Lindgarde 2000 [39]	U	U	U	L	U	U	L	L	L	L	L	H
Ma 2013 [40]	L	U	H	L	L	H	L	L	L	L	L	L
Martin 2008 [41]	U	U	H		U			H		L	L	H
Miles 2002 [42]	U	U	U	L	U	U	H	H	H	U	L	H
Morey 2012 [43]	U	L	H	L	L	U	L	L	L	L	L	L
Muls 2001 [44]	U	U	U	L	U	U	L	L	L	L	L	H
Nakade 2012 [45]	U	U	H		U			L		H	L	L
Nanchahal 2012 [46]	L	U	H		L			H		L	L	L
Ockene 2012 [47]	U	U	H	L	U		L	L		H	L	L
Parikh 2010 [48]	L	U	H	L	U		L	L		H	L	L
Patrick 2011 [49]	L	U	H		L			H		L	L	H
Penn 2009 [50]	L	U	H	L	U		H	L		L	L	H
Ross 2012 [51]	L	U	H	L	L		L	L		L	L	L
Rossner 2000 [52]	U	U	U	L	U	U	H	H	H	L	L	H
Seifarth 2013 [53]	H	H	H			H			L	L	L	U
Sjostrom 1998 [54]	L	U	U	L	U	U	L	L	L	L	L	H
Smith 2011 [55]	U	U	U			U			L	L	L	H
Stevens 1993 [56]	U	L	U		L	U		L	L	L	L	L
Stevens 2001 [57]	U	U	H	L	L		L	L		L	L	L
Swinburn 2005 [58]	L	U	U	L	U	L	L	L	L	H	L	H
ter Bogt 2011 [59]	L	U	H	L	U		L	L		L	L	L
Torgerson 2004 [60]	L	L	L	L	L	L	L	L	L	U	L	H
Tsai 2010 [61]	L	L	H	L	H	H	L	L	L	U	L	H
Van Gaal 1998 [62]	U	U	U			U			L	L	L	H
Vissers 2010 [63]	U	U	H	L	U		L	L		L	L	H
Wadden 2011 [64]	L	U	H	L	U	U	L	L	L	L	L	L
Wood 1988 [65]	L	L	H	L	U		L	L		L	L	L
Wood 1991 [66]	U	U	H	L	U		L	L		L	L	L
Woollard 2003 [67]	L	U	H	L	H		L	L		L	L	L

Note: OBJ = objective outcome, SUB = Subjective Outcome; S-R = Self-Reported Outcome. *The Cochrane risk-of-bias tool was used to assess the risk of bias for each study. Low risk (L) = bias, if present, is unlikely to alter the results seriously, unclear risk (U) = bias raises some doubt about the results, high risk (H) = bias may alter the results seriously.

References

1. *Cochrane handbook for systematic reviews of interventions*. Version 5.1.0 ed. New York, NY: John Wiley & Sons, Ltd. Publications; 2011.
2. Anderssen S, Holme I, Urdal P, Hjermann I. Diet and exercise intervention have favourable effects on blood pressure in mild hypertensives: the Oslo Diet and Exercise Study (ODES). *Blood Press* 1995;4(6):343-9.
3. Andrews RC, Cooper AR, Montgomery AA, Norcross AJ, Peters TJ, Sharp DJ, et al. Diet or diet plus physical activity versus usual care in patients with newly diagnosed type 2 diabetes: the Early ACTID randomised controlled trial. *Lancet* 2011;378(9786):129-39.
4. Appel LJ, Clark JM, Yeh HC, Wang NY, Coughlin JW, Daumit G, et al. Comparative effectiveness of weight-loss interventions in clinical practice. *N Engl J Med* 2011;365(21):1959-68.
5. Balducci S, Zanuso S, Nicolucci A, Fernando F, Cavallo S, Cardelli P, et al. Anti-inflammatory effect of exercise training in subjects with type 2 diabetes and the metabolic syndrome is dependent on exercise modalities and independent of weight loss. *Nutr Metab Cardiovasc Dis* 2010;20(8):608-17.
6. Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I, et al. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2002;20(11):2257-67.
7. Bennett GG, Warner ET, Glasgow RE, Askew S, Goldman J, Ritzwoller DP, et al. Obesity treatment for socioeconomically disadvantaged patients in primary care practice. *Arch Intern Med* 2012;172(7):565-74.
8. Berne C, Orilstat Swedish Type 2 Diabetes Study Group. A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin. *Diabetes Med* 2005;22(5):612-8.
9. Broom I, Wilding J, Stott P, Myers N; UK Multimorbidity Study Group. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. *Int J Clin Pract* 2002;56(7):494-9.
10. Broom I, Hughes E, Dodson P, Reckless J; ORILSTAT UK Study Group. The role of orlistat in the treatment of obese patients with mild to moderate hypercholesterolaemia: consequences for coronary risk. *Brit J Cardio* 2002;9(8):460-8.

11. Burke V, Beilin LJ, Cutt HE, Mansour J, Wilson A, Mori TA. Effects of a lifestyle programme on ambulatory blood pressure and drug dosage in treated hypertensive patients: a randomized controlled trial. *J Hypertens* 2005;23(6):1241-9.
12. Burtscher M, Gatterer H, Dünwald T, Pesta D, Faulhaber M, Netzer N, et al. Effects of supervised exercise on gamma-glutamyl transferase levels in patients with isolated impaired fasting glucose and those with impaired fasting glucose plus impaired glucose tolerance. *Exp Clin Endocrinol Diabetes* 2012;120(8):445-50.
13. Christian JG, Bessesen DH, Byers TE, Christian KK, Goldstein MG, Bock BC. Clinic-based support to help overweight patients with type 2 diabetes increase physical activity and lose weight. *Arch Intern Med* 2008;168(2):141-6.
14. Cohen MD, D'Amico FJ, Merenstein JH. Weight reduction in obese hypertensive patients. *Fam Med* 1991;23(1):25-8.
15. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. *JAMA* 1999;281(3):235-42.
16. Dekkers JC, van Wier MF, Ariëns GA, Hendriksen IJ, Pronk NP, Smid T, et al. Comparative effectiveness of lifestyle interventions on cardiovascular risk factors among a Dutch overweight working population: a randomized controlled trial. *BMC Public Health* 2011;11(49).
17. de Mello VD, Lindström J, Eriksson J, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Sundvall J, et al. Insulin secretion and its determinants in the progression of impaired glucose tolerance to type 2 diabetes in impaired glucose-tolerant individuals: the Finnish Diabetes Prevention Study. *Diabetes Care* 2012;35(2):211-7.
18. Derosa G, Mugellini A, Ciccarelli L, Fogari R. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. *Clin Ther* 2003;25(4):1107-22.
19. Derosa G, Cicero AF, D'Angelo A, Fogari E, Maffioli P. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes. *J Clin Pharm Ther* 2012;37(2):187-95.
20. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. [Erratum in *Diabetes Care* 1999;22(8):1389]. *Diabetes Care* 1999;22(4):623-34.
21. Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. *Int J Obes Relat Metab Disord* 2000;24(3):306-13.

22. Fontbonne A, Charles MA, Juhan-Vague I, Bard JM, André P, Isnard F, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. *Diabetes Care* 1996;19(9):920-6.
23. Foster-Schubert KE, Alfano CM, Duggan CR, Xiao L, Campbell KL, Kong A, et al. Effect of diet and exercise, alone or combined, on weight and body composition in overweight-to-obese postmenopausal women. *Obesity (Silver Spring)* 2012;20(8):1628-38.
24. Haapala I, Barengo NC, Biggs S, Surakka L, Manninen P. Weight loss by mobile phone: a 1-year effectiveness study. *Public Health Nutr* 2009;12(12):2382-91.
25. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. *Diabetes Obes Metab* 2002;4(6):415-23.
26. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. *Arch Fam Med* 2000;9(2):160-7.
27. He H, Zhao Z, Chen J, Ni Y, Zhong J, Yan Z, et al. Metformin-based treatment for obesity-related hypertension: a randomized, double-blind, placebo-controlled trial. *J Hypertens* 2012;30(7):1430-9.
28. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. *Diabetes Care* 1998;21(8):1288-94.
29. Janney CA, Jakicic JM. The influence of exercise and BMI on injuries and illnesses in overweight and obese individuals: a randomized control trial. *Int J Behav Nutr Phys Act* 2010;7:1.
30. Janus ED, Best JD, Davis-Lameloise N, Philpot B, Hernan A, Bennett CM, et al. Scaling-up from an implementation trial to state-wide coverage: results from the preliminary Melbourne Diabetes Prevention Study. *Trials* 2012;13:152.
31. Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. *Diabetes Care* 2002;25(6):1033-41.
32. Krempf M, Louvet JP, Allanic H, Miloradovich T, Joubert JM, Attali JR. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity. *Int J Obes Relat Metab Disord* 2003;27(5):591-7.

33. Kirby ML, Beatty S, Stack J, Harrison M, Greene I, McBrinn S, et al. Changes in macular pigment optical density and serum concentrations of lutein and zeaxanthin in response to weight loss. *Br J Nutr* 2011;105(7):1036-46.
34. Kopelman P, Groot GH, Rissanen A, Rossner S, Toubro S, Palmer R, et al. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). *Obesity* 2010;18(1):108-15.
35. Kulzer B, Hermanns N, Gorges D, Schwarz P, Haak T. Prevention of diabetes self-management program (PREDIAS): effects on weight, metabolic risk factors, and behavioral outcomes. *Diabetes Care* 2009;32(7):1143-6.
36. Langford HG, Blaufox MD, Oberman A, Hawkins CM, Curb JD, Cutter GR, et al. Dietary therapy slows the return of hypertension after stopping prolonged medication. *JAMA* 1985;253(5):657-64.
37. Lim SS, Noakes M, Keogh JB, Clifton PM. Long-term effects of a low carbohydrate, low fat or high unsaturated fat diet compared to a no-intervention control. *Nutr Metab Cardiovasc Dis* 2010;20(8):599-607.
38. Lim SS, Norman RJ, Clifton PM, Noakes M. The effect of comprehensive lifestyle intervention or metformin on obesity in young women. *Nutr Metab Cardiovasc Dis* 2011;21(4):261-8.
39. Lindgärde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. *J Intern Med* 2000;248(3):245-54.
40. Ma J, Yank V, Xiao L, Lavori PW, Wilson SR, Rosas LG, et al. Translating the Diabetes Prevention Program lifestyle intervention for weight loss into primary care: a randomized trial. *JAMA Intern Med* 2013;173(2):113-21.
41. Martin PD, Dutton GR, Rhode PC, Horswell RL, Ryan DH, Brantley PJ. Weight loss maintenance following a primary care intervention for low-income minority women. *Obesity (Silver Spring)* 2008;16(11):2462-7.
42. Miles JM, Leiter L, Hollander P, Wadden T, Anderson JW, Doyle M, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. *Diabetes Care* 2002;25(7):1123-8.
43. Morey MC, Pieper CF, Edelman DE, Yancy WS, Green JB, Lum H, et al. Enhanced fitness: a randomized controlled trial of the effects of home-based physical activity counseling on glycemic control in older adults with prediabetes mellitus. *J Am Geriatr Soc* 2012;60(9):1655-62.

44. Muls E, Kolanowski J, Scheen A, Van Gaal L.; ObelHyx Study Group. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. *Int J Obes Relat Metab Disord* 2001;25(11):1713-21.
45. Nakade M, Aiba N, Suda N, Morita A, Miyachi M, Sasaki S, et al. Behavioral change during weight loss program and one-year follow-up: Saku Control Obesity Program (SCOP) in Japan. *Asia Pac J Clin Nutr* 2012;21(1):22-34.
46. Nanchahal K, Power T, Holdsworth E, Hession M, Sorhaindo A, Griffiths U, et al. A pragmatic randomised controlled trial in primary care of the Camden Weight Loss (CAMWEL) programme. *BMJ Open* 2012;2(3):e000793.
47. Ockene IS, Tellez TL, Rosal MC, Reed GW, Mordes J, Merriam PA, et al. Outcomes of a Latino community-based intervention for the prevention of diabetes: the Lawrence Latino Diabetes Prevention Project. *Am J Public Health* 2012;102(2):336-42.
48. Parikh P, Simon EP, Fei K, Looker H, Goytia C, Horowitz CR. Results of a pilot diabetes prevention intervention in East Harlem, New York City: Project HEED. *Am J Public Health* 2010;100(Suppl 1):S232-9.
49. Patrick K, Calfas KJ, Norman GJ, Rosenberg D, Zabinski MF, Sallis JF, et al. Outcomes of a 12-month web-based intervention for overweight and obese men. *Ann Behav Med* 2011;42(3):391-401.
50. Penn L, White M, Oldroyd J, Walker M, Alberti KG, Mathers JC. Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. *BMC Public Health* 2009;9:342.
51. Ross R, Lam M, Blair SN, Church TS, Godwin M, Hotz SB, et al. Trial of prevention and reduction of obesity through active living in clinical settings: a randomized controlled trial. *Arch Intern Med* 2012;172(5):414-24.
52. Rössner S, Sjöström L, Noack R, Meinders AE, Nosedá G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. *Obes Res* 2000;8(1):49-61.
53. Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. *Exp Clin Endocrinol Diabetes* 2013;121(1):27-31.
54. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. *Lancet* 1998;352(9123):167-72.

55. Smith SR, Stenlof KS, Greenway FL, McHutchison J, Schwartz SM, Dev B, et al. Orlistat 60 mg reduces visceral adipose tissue: a 24-week randomized, placebo-controlled, multicenter trial. *Obesity* 2011;19(9):1796-803.
56. Stevens VJ, Corrigan SA, Obarzanek E, Bernauer E, Cook NR, Hebert P, et al. Weight loss intervention in phase 1 of the Trials of Hypertension Prevention. The TOHP Collaborative Research Group. *Arch Intern Med* 1993;153(7):849-58.
57. Stevens VJ, Obarzanek E, Cook NR, Lee IM, Appel LJ, Smith WD, et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. *Ann Intern Med* 2001;134(1):1-11.
58. Swinburn BA, Carey D, Hills AP, Hooper M, Marks S, Proietto J, et al. Effect of orlistat on cardiovascular disease risk in obese adults. *Diabetes Obes Metab* 2005;7(3):254-62.
59. ter Bogt NC, Milder IE, Bemelmans WJ, Beltman FW, Broer J, Smit AJ, et al. Changes in lifestyle habits after counselling by nurse practitioners: 1-year results of the Groningen Overweight and Lifestyle study. *Public Health Nutr* 2011;14(6):995-1000.
60. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. *Diabetes Care* 2004;27(1):155-61.
61. Tsai AG, Wadden TA, Rogers MA, Day SC, Moore RH, Islam BJ. A primary care intervention for weight loss: results of a randomized controlled pilot study. *Obesity* 2010;18(8):1614-8.
62. Van Gaal LF, Broom JI, Enzi G, Toplak H. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. *Eur J Clin Pharmacol* 1998;54(2):125-32.
63. Vissers D, Verrijken A, Mertens I, Van Gils C, Van de Sompel A, Truijten S, et al. Effect of long-term whole body vibration training on visceral adipose tissue: a preliminary report. *Obes Facts* 2010;3(2):93-100.
64. Wadden TA, Volger S, Sarwer DB, Vetter ML, Tsai AG, Berkowitz RI, et al. A two-year randomized trial of obesity treatment in primary care practice. *N Engl J Med* 2011;365(21):1969-79.
65. Wood PD, Stefanick ML, Dreon DM, Frey-Hewitt B, Garay SC, Williams PT, et al. Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. *N Engl J Med* 1988;319(18):1173-9.

66. Wood PD, Stefanick ML, Williams PT, Haskell WL. The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women. *N Engl J Med* 1991;325(7):461-6.
67. Woollard J, Burke V, Beilin LJ, Verheijden M, Bulsara MK. Effects of a general practice-based intervention on diet, body mass index and blood lipids in patients at cardiovascular risk. *J Cardiovasc Risk* 2003;10(1):31-40.